Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to LP-284 for the treatment of soft tissue sarcomas, marking the third orphan designation for the program and the sixth overall across the company's clinical pipeline. This designation expands LP-284 beyond hematologic malignancies into solid tumors and reflects its synthetic lethal mechanism targeting DNA repair deficiencies, which are common in adult soft tissue sarcomas.
According to Lantern, the designation supports an accelerated regulatory pathway for LP-284 as it continues Phase 1 evaluation in B-cell non-Hodgkin lymphomas and advances development in additional rare cancer indications. The company's proprietary RADR® AI platform integrates hundreds of billions of data points to identify biomarkers, predict drug response, and design smarter clinical trials. Lantern's clinical-stage pipeline includes LP-184, LP-284, and LP-300, each targeting genomically defined patient populations.
For more details on the press release, visit https://ibn.fm/6FcBo. To stay updated on the latest news and updates relating to LTRN, visit the company's newsroom at https://ibn.fm/LTRN.
